Enable your next discovery

Illuminate the intricacies of the immune response with soluble HLA

3D molecular structure of an HLA protein

Soluble HLA Technology

Pure Protein’s pioneering approach produces soluble forms of HLA Class I and II proteins (sHLA). These molecules support the development of diagnostic and therapeutic applications by creating properly configured and reproducible native HLA proteins in an industrialized and standardized process. This proprietary technology delivers naturally glycosylated, endogenously loaded, natively folded, recombinant molecules lacking transmembrane and cytosolic domains, that are synthesized in mammalian cells and purified using affinity chromatography.

sHLA Class I proteins
sHLA Class II proteins
Years of research
3D molecular structure of an HLA protein

Choose from a range of HLA products and services

Soluble HLA Proteins Class I

Mammalian produced, endogenously loaded, and naturally folded recombinant soluble HLA Class I proteins

Soluble HLA Proteins Class II

Mammalian produced, zipper stabilized, endogenously loaded, and naturally folded recombinant soluble HLA Class II proteins

Peptide Validation and Screening Services

Competition-based HLA peptide binding assays for the validation and screening of putative T cell epitopes

Pure protein offices

About us

Pure Protein, L.L.C. (Pure Protein) is an HLA company that has developed comprehensive analytical capabilities in the field of human leukocyte antigen (HLA) immunology and an approach to produce soluble forms of the HLA molecule (sHLA). Pure Protein provides technology and expertise to advance novel therapies and diagnostic tools across a wide range of applications, covering areas of antibody mediated rejection in transplantation and peptide epitope based therapeutics in oncology, autoimmunity, and infectious diseases.


The Search for Vaccine Targets For COVID-19

The University of Oklahoma Health Sciences Center has launched a research collaboration with Pure MHC, LLC an innovative biotechnology company, to work toward the development of a vaccine for the COVID-19 virus.

  • "With OU, we are acquiring the actual COVID-19 virus, and we will infect cells and look for the targets on the infected cells. We will use those targets to either develop a vaccine or to directly target them with something like monoclonal antibodies."

Curtis McMurtrey, Ph.D.,

Director of Immuno-Proteomics for Pure MHC and a graduate of the OU Health Sciences Center.

Chris McMurtrey, director of immuno-proteomics for Pure MHC

Latest news from Pure Protein